Bnp Paribas Asset Management Holding S.A. Bei Gene, Ltd. Transaction History
Bnp Paribas Asset Management Holding S.A.
- $38.7 Billion
- Q2 2024
A detailed history of Bnp Paribas Asset Management Holding S.A. transactions in Bei Gene, Ltd. stock. As of the latest transaction made, Bnp Paribas Asset Management Holding S.A. holds 97,629 shares of BGNE stock, worth $21.3 Million. This represents 0.04% of its overall portfolio holdings.
Number of Shares
97,629
Previous 98,073
0.45%
Holding current value
$21.3 Million
Previous $15.3 Million
9.19%
% of portfolio
0.04%
Previous 0.04%
Shares
21 transactions
Others Institutions Holding BGNE
# of Institutions
213Shares Held
45.5MCall Options Held
106KPut Options Held
93.1K-
Baker Bros. Advisors LP New York, NY10.6MShares$2.31 Billion20.04% of portfolio
-
Capital International Investors Los Angeles, CA7.01MShares$1.53 Billion0.21% of portfolio
-
Hhlr Advisors, Ltd. Grand Cayman, E95.18MShares$1.13 Billion19.1% of portfolio
-
Primecap Management CO Pasadena, CA4.99MShares$1.09 Billion0.52% of portfolio
-
Baillie Gifford & CO3.68MShares$805 Million0.42% of portfolio
About BeiGene, Ltd.
- Ticker BGNE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 103,700,000
- Market Cap $22.7B
- Description
- BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...